Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.
Jim Cramer weighs in on Colgate-Palmolive, Biogen Idec, Covanta, Cypress Semiconductor, Carrizo Oil & Gas, Allstate and more.
The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Jim Cramer weighs in on Spirit Airlines, Southwest, Amgen, Biogen Idec, Liberty Oilfield Services, The Chefs Warehouse, Under Armour and more.
Jim Cramer says news on tariffs, FANG stocks, positive research, and the corporate outlook are fueling a stock market surprise.
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
The Dow Jones Industrial Average falls Tuesday after earnings disappoint. The S&P 500 falls for the 12th time in 14 sessions.
U.S. stock futures tumble sharply as investors focus on slowing economic growth and simmering geopolitical tensions; Caterpillar, McDonald's, Verizon and 3M report earnings; Arconic is mulling an $11 billion offer from Apollo, a report says; a judge cuts the jury award against Bayer's Roundup.
Biogen (Nasdaq:BIIB) and Samsung Bioepis Co., Ltd.
Straying from these names could land you in quicksand as the 4th quarter begins.
The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Short-term price action may be volatile, but this name is still bullish long term.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
Shares fell by more than 11% in after hours trading Wednesday.
Even with the market looking wobbly, there are good bargains to be found. Here are several suggestions from TheStreet's newsroom.
TOKYO and CAMBRIDGE, Mass., July 25, 2018 /PRNewswire/ -- Eisai Co.
TOKYO and CAMBRIDGE, Mass., July 25, 2018 /PRNewswire/ -- Eisai Co.
The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.
Don't buy up when there's nothing but rampant pin action.
The Dow ended higher, breaking a 3-day skid, while the Nasdaq rebounded to end little changed after hitting a record high earlier.
The biotech giant also raised its 2018 guidance for both revenue and earnings.
U.S. stock futures rise on Tuesday, with solid corporate earnings boosting shares on Wall Street; Alphabet is set to open at a record high after the parent of Google posts a significant earnings beat; AT&T and Verizon highlight Tuesday's earnings calendar.
The Cambridge, Mass.-based biotech is scheduled to unveil its second-quarter results before the market open on July 24.
Positive readings from the biotech giant's Alzheimer's drug could drive the stock to as high as $393.
Jim Cramer is bullish on Target, Biogen Idec, Regions Financial, Lockheed Martin, US Bancorp, BlackRock and more.
Jim Cramer says financial payment companies are the most beloved in the market right now. He explains digitized payment companies. And love.
The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
